The combination of NLRP3 inhibition and anti-PD-1 antibody has obtained a synergized effect via the suppression of the function of MDSCs.379 In parallel with this, the activation of NLRP3 is also responsible for the role of tumorous PD-L1 in the resistance to anti-PD-1 immunotherapy through the regulation of MDSCs.380 In aggregate, inflammasomes play an oncogenic role in melanoma via the simultaneous effect on both tumor cell behavior and antitumor immunity. This evidence concerns the gene CD274 and neoplasm.